GHRP-2 and LL-37 Interaction

Synergistic
Mechanism-based 47% confidence

GHRP-2 and LL-37 have a synergistic interaction with 47% confidence. GHRP-2 and LL-37 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. These compounds primarily affect different organ systems.

Compound Profiles

GHRP-2

Growth Hormone Releasing Peptide-2 | Pralmorelin

GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops.

Half-life: ~30 minutes Typical dose: 100-300 mcg growth hormone, weight loss
ghrelin receptor carcinogenic riskinsulin disruptingprolactin elevatingteratogenic
View full profile

LL-37

Human Cathelicidin | Antimicrobial Peptide

Provides direct antimicrobial activity through membrane disruption, promotes wound healing by enhancing keratinocyte migration and angiogenesis, and modulates immune responses without systemic exposure when used topically..

Half-life: Short (rapid proteolytic degradation) Typical dose: 0.5-1.6 mg/mL topical gel or 100-150 mcg injectable immune, healing
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low
Blood Vessels
low

Frequently Asked Questions

Can I take GHRP-2 with LL-37?

Yes, GHRP-2 and LL-37 can generally be taken together. GHRP-2 and LL-37 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.

Is GHRP-2 and LL-37 safe together?

Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.

What are the interactions between GHRP-2 and LL-37?

GHRP-2 and LL-37 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time GHRP-2 and LL-37?

GHRP-2 has a half-life of ~30 minutes and LL-37 has a half-life of Short (rapid proteolytic degradation). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: GHRP-2 vs LL-37

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.